Compositions comprising luteolin and / or luteolin-7-o-Β-d-glucoside, methods of making and using the same

WO2026142997A1PCT designated stage Publication Date: 2026-07-02ACCESS BUSINESS GROUP INTERNATIONAL LLC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
ACCESS BUSINESS GROUP INTERNATIONAL LLC
Filing Date
2025-12-22
Publication Date
2026-07-02

AI Technical Summary

Technical Problem

There is a need for natural, small molecule triple agonists that can activate all three receptors - GLP-1R, GIPR, and GCGR - to effectively treat obesity and type 2 diabetes mellitus, as current treatments primarily focus on dual agonists with limited efficacy.

Method used

Luteolin and luteolin-7-O-β-D-glucoside are developed as natural, small molecule triple agonists that activate all three receptors, GLP-1R, GIPR, and GCGR, with concentrations ranging from 5-40 pM for luteolin and 10-1000 pM for luteolin-7-O-β-D-glucoside, formulated in various oral compositions for weight management and diabetes control.

Benefits of technology

The compositions demonstrate significant agonistic activity on all three receptors, offering enhanced weight loss and metabolic control, with luteolin showing at least 20-fold activation and luteolin-7-O-β-D-glucoside showing at least 10-fold activation, providing effective treatment and prevention of obesity and type 2 diabetes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025060886_02072026_PF_FP_ABST
    Figure US2025060886_02072026_PF_FP_ABST
Patent Text Reader

Abstract

Described herein are compositions formulated for oral administration comprising luteolin, luteolin-7-O-β-D-glucoside, or a mixture thereof, wherein luteolin, luteolin-7-O-β-D-glucoside, or the mixture thereof, activate all of: glucagon-like peptide 1 receptor (GLP-1R), glucose-dependent insulinotropic peptide receptor (GIPR), and glucagon receptor (GCGR). Luteolin and luteolin-7-O-β-D-glucoside are triple agonists of GLP-1, GIPR and GCGR. Also, described herein are methods for treating and / or preventing type 2 diabetes mellitus and obesity by administering the described compositions. Also, described herein is a method for activating all of GLP-1R, GIPR, and GCGR, comprising providing a composition comprising a triple agonist for all of GLP-1R, GIPR, and GCGR, where the triple agonist is luteolin and / or luteolin-7-O-β-D-glucoside.
Need to check novelty before this filing date? Find Prior Art